ID-JPL934 for Abnormal Bowel Movement

NCT ID: NCT03395626

Last Updated: 2018-01-30

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: NA
• Total Enrollment: 112 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2017-07-12
• Study Completion Date: 2018-03-31

Brief Summary

Probiotics, which are part of the human body, are microorganisms, which are known to have beneficial effects when consumed in a certain amount, and have the function of controlling intestinal flora and inhibiting inflammation. Recently, probiotics have received much attention in the treatment of hypersensitivity syndrome. The aim of this study was to investigate the effect of probiotic strains, ID-JPL934, in the diagnosis of irritable bowel syndrome.

Overall satisfaction with improvement of bowel habits such as diarrhea and constipation as well as abdominal discomfort and abdominal discomfort in the group receiving ID-JPL934 capsules (test food group or test group) and control group (control food group or control group) (0-10 point visual analogue scale) for each symptom before and after ingestion to evaluate the degree of improvement of the symptoms. The purpose of this study was to investigate the relationship between bacterial composition changes in the stool and the improvement of symptoms in the patients before and after ingestion.

Conditions

Abnormal Bowel Movement Such as Constipation, Diarrhea, Abdominal Pain

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: TRIPLE

Study Groups

ID-JPL934

probiotics 20%, corn starch 80%

Group Type: EXPERIMENTAL

ID-JPL934

Intervention Type: DIETARY_SUPPLEMENT

probiotics

placebo

corn starch 100%

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DIETARY_SUPPLEMENT

corn starch

Interventions

ID-JPL934

probiotics

Intervention Type: DIETARY_SUPPLEMENT

Placebo

corn starch

Intervention Type: DIETARY_SUPPLEMENT

Eligibility Criteria

Inclusion Criteria

1. Korean men and women aged over 19 and 80

2. Adults with the following criteria (1) If the symptoms are relieved by bowel movements and changes in the number of bowel movements with less than two stomach complaints or stomach complaints every three months (2), these two forms of bowel movements have started (3)

3. Methodological-fractive women or fertile women who are negative during pregnancy diagnostic tests (urine or seron- hCG). An appropriate method of birth control (e.g., " oral contraceptive " or bi-fertility) during an examination

4. People who have no problems in their nerves and mental systems and who can make their own doctors clear

5. The person who agreed in writing to this test

Exclusion Criteria

1. Persons with hypersensitivity to probiotics

2. Pregnant or lactating women

3. People who have received other clinical trial drugs within the first 3 months of visit 1. However, in the case of lactic acid bacteria preparation, the test can be taken after a two week absence period.

4. A person who believes that the participant is in a condition or situation in which participation in the clinical trial may be hazardous to the participant,

5. Patients with severe congestive heart failure or severe angina

6. If the patient is diagnosed as having urticaria or immunosuppression

7. Patients who are taking or taking medications (formulants, lactic acid bacteria) that may affect the test food, probiotics, or during the test period. However, if you are taking the drug, you can take the test after two weeks of abstinence.

8. If the systolic blood pressure measured at Visit 1 is greater than 160 mmHg or diastolic blood pressure is greater than 100 mmHg and hypertension is not controlled regardless of whether the medication is administered or not.

9. Patients with uncontrolled endocrine diseases (such as diabetes), metabolic diseases (eg secondary hyperlipidemia) or hypothyroidism (subjects with a history of hypothyroidism) should receive a stable thyroid hormone supplement for at least 4 weeks prior to visit 1 If you are on therapy, you can participate in this test only if the TSH level measured at Visit 2 is within the normal range.)

10. If kidney function is impaired at visit 1 (creatinine> 2.0 mg / dL) or nephrotic syndrome is observed

11. If the cancer has developed within the past 5 years (unless it is determined to be cured)

12. If there is a history of mental instability and drug / alcohol abuse within the past 5 years, or if major psychiatric illnesses are not adequately controlled and stabilized by medication

13. Visits 1 If you have taken mental nerve agents within the previous 3 months

14. If you take a systemic steroid preparation within 1 month before visit 1

15. Patients who underwent abdominal surgery except for appendectomy, hernia surgery, and cesarean section

16. People who are suffering from hypersensitivity syndrome in the ROME Ⅲ standard

17. Any person deemed inappropriate for the judgment of the clinician

• Minimum Eligible Age: 19 Years
• Maximum Eligible Age: 80 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Seoul National University Hospital

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Seoul National University Bungdang Hospital

Seongnam-si, Gyeonggi-do, South Korea

Countries

South Korea

References

Shin CM, Choi YJ, Lee DH, Moon JS, Kim TY, Kim YK, Lee WH, Yoon H, Park YS, Kim N. Validity and safety of ID-JPL934 in lower gastrointestinal symptom improvement. Sci Rep. 2021 Jun 22;11(1):13046. doi: 10.1038/s41598-021-92007-3.

Reference Type: DERIVED

PMID: 34158518 (View on PubMed)

Other Identifiers

ID-JPL934

Identifier Type: -

Identifier Source: org_study_id